Jubilant Pharmova's Q2 consolidated profit fell 74% to about Rs 31 crore from Rs 120 crore a year earlier, while revenue rose 21%.
Results · 14 Nov 2026 · Jubilant Pharmova (JUBLPHARMA)
| Latest quarter | ₹ Cr |
|---|---|
| Operating profit | 255 |
| Net profit | 31 |
EBITDA fell 27% to about Rs 255 crore and the margin dropped to 10.7% from 17.8%. Generics revenue rose 64%, but the generics EBITDA margin was 7%.
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.